Leerink Swann Upgrades MedAssets To Outperform
Analysts at Leerink Swann upgraded MedAssets (NASDAQ: MDAS) from Market Perform to Outperform.
The target price for MedAssets is set to $26.
MedAssets shares have fallen 6.51% over the past 52 weeks, while the S&P 500 index has gained 19.79% in the same period.
MedAssets' shares rose 0.28% to close at $21.25 yesterday.
Latest Ratings for MDAS
|Jan 2016||SunTrust Robinson Humphrey||Terminates||Neutral|
|Nov 2015||JP Morgan||Assumes||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.